Donald Craig Simonson, M.D., S.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperglycemia | 15 | 2024 | 1373 | 1.700 |
Why?
|
| Diabetes Mellitus, Type 1 | 41 | 2023 | 3336 | 1.630 |
Why?
|
| Blood Glucose | 75 | 2023 | 6256 | 1.500 |
Why?
|
| Hypoglycemia | 22 | 2023 | 861 | 1.490 |
Why?
|
| Gastric Bypass | 7 | 2024 | 812 | 1.250 |
Why?
|
| Insulin Resistance | 29 | 2023 | 3864 | 1.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 41 | 2024 | 11725 | 1.150 |
Why?
|
| Hypoglycemic Agents | 18 | 2020 | 2872 | 1.110 |
Why?
|
| Insulin | 62 | 2022 | 6580 | 1.100 |
Why?
|
| Obesity, Morbid | 4 | 2022 | 1213 | 0.820 |
Why?
|
| Bariatric Surgery | 5 | 2024 | 952 | 0.790 |
Why?
|
| Hyperinsulinism | 5 | 2022 | 415 | 0.740 |
Why?
|
| Gastroplasty | 2 | 2019 | 142 | 0.720 |
Why?
|
| Gyrus Cinguli | 2 | 2022 | 1091 | 0.600 |
Why?
|
| Epinephrine | 19 | 1999 | 792 | 0.580 |
Why?
|
| Diabetes Mellitus | 17 | 2023 | 5751 | 0.580 |
Why?
|
| Glutamic Acid | 2 | 2020 | 1169 | 0.540 |
Why?
|
| Glucagon | 18 | 1998 | 533 | 0.500 |
Why?
|
| Insulin, Long-Acting | 1 | 2012 | 57 | 0.430 |
Why?
|
| Vasodilation | 3 | 2006 | 944 | 0.420 |
Why?
|
| Glucose | 27 | 2023 | 4397 | 0.410 |
Why?
|
| Hydrocortisone | 15 | 1999 | 1826 | 0.410 |
Why?
|
| Obesity | 14 | 2022 | 12745 | 0.400 |
Why?
|
| Glipizide | 5 | 1998 | 47 | 0.400 |
Why?
|
| Thiazolidinediones | 2 | 2006 | 476 | 0.390 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 1125 | 0.390 |
Why?
|
| Intra-Abdominal Fat | 1 | 2014 | 591 | 0.350 |
Why?
|
| Glucose Clamp Technique | 14 | 2010 | 266 | 0.340 |
Why?
|
| Lipoproteins, HDL | 1 | 2013 | 638 | 0.330 |
Why?
|
| Growth Hormone | 11 | 1996 | 705 | 0.330 |
Why?
|
| Triglycerides | 5 | 2013 | 2454 | 0.320 |
Why?
|
| Hormones | 3 | 1998 | 889 | 0.300 |
Why?
|
| Weight Loss | 7 | 2019 | 2622 | 0.290 |
Why?
|
| Laparoscopy | 1 | 2019 | 2151 | 0.290 |
Why?
|
| Glyburide | 7 | 1998 | 113 | 0.290 |
Why?
|
| Adipose Tissue | 4 | 2013 | 3279 | 0.280 |
Why?
|
| Quality of Life | 10 | 2019 | 12804 | 0.270 |
Why?
|
| Adult | 87 | 2024 | 214055 | 0.270 |
Why?
|
| Norepinephrine | 13 | 1998 | 909 | 0.260 |
Why?
|
| Memory, Short-Term | 1 | 2011 | 975 | 0.250 |
Why?
|
| Middle Aged | 65 | 2024 | 213383 | 0.250 |
Why?
|
| Male | 91 | 2024 | 350118 | 0.250 |
Why?
|
| Adrenocorticotropic Hormone | 5 | 1999 | 648 | 0.240 |
Why?
|
| Female | 90 | 2024 | 380194 | 0.230 |
Why?
|
| Fasting | 10 | 2021 | 1593 | 0.230 |
Why?
|
| Glucose Tolerance Test | 10 | 2013 | 1150 | 0.230 |
Why?
|
| Diabetes Complications | 4 | 2019 | 1359 | 0.220 |
Why?
|
| Bariatrics | 1 | 2023 | 34 | 0.220 |
Why?
|
| Humans | 124 | 2024 | 744343 | 0.200 |
Why?
|
| Inositol | 1 | 2022 | 218 | 0.190 |
Why?
|
| Naltrexone | 2 | 2013 | 307 | 0.190 |
Why?
|
| Lipids | 7 | 2014 | 3305 | 0.190 |
Why?
|
| Liver | 16 | 2021 | 7474 | 0.190 |
Why?
|
| Fatty Acids, Nonesterified | 9 | 2004 | 402 | 0.180 |
Why?
|
| Life Style | 4 | 2019 | 3835 | 0.180 |
Why?
|
| Metformin | 2 | 2020 | 835 | 0.170 |
Why?
|
| Patient Satisfaction | 2 | 2012 | 3396 | 0.170 |
Why?
|
| Metyrapone | 2 | 1996 | 23 | 0.160 |
Why?
|
| Overweight | 2 | 2022 | 2371 | 0.160 |
Why?
|
| Hypertension | 9 | 2006 | 8480 | 0.160 |
Why?
|
| Insulin Infusion Systems | 5 | 1992 | 212 | 0.160 |
Why?
|
| Gastrectomy | 1 | 2022 | 663 | 0.150 |
Why?
|
| beta-Endorphin | 1 | 1996 | 53 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 1676 | 0.140 |
Why?
|
| Benzodiazepines | 2 | 2013 | 1101 | 0.140 |
Why?
|
| Hospitalization | 4 | 2023 | 10262 | 0.140 |
Why?
|
| Medication Reconciliation | 1 | 2018 | 151 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2007 | 2684 | 0.140 |
Why?
|
| Thiazoles | 1 | 2003 | 1483 | 0.130 |
Why?
|
| Oxygen Consumption | 4 | 2012 | 1869 | 0.130 |
Why?
|
| Adrenal Cortex | 1 | 1996 | 140 | 0.130 |
Why?
|
| Vagotomy, Proximal Gastric | 1 | 2014 | 8 | 0.130 |
Why?
|
| Jejunum | 1 | 2017 | 480 | 0.130 |
Why?
|
| Reference Values | 10 | 2010 | 4982 | 0.130 |
Why?
|
| Metabolome | 1 | 2021 | 895 | 0.130 |
Why?
|
| Homeostasis | 7 | 2013 | 3340 | 0.130 |
Why?
|
| Prolactin | 1 | 1996 | 669 | 0.120 |
Why?
|
| Body Mass Index | 11 | 2024 | 12720 | 0.120 |
Why?
|
| Brain | 6 | 2017 | 26385 | 0.120 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2014 | 87 | 0.120 |
Why?
|
| Anastomosis, Surgical | 1 | 2017 | 987 | 0.120 |
Why?
|
| Synaptic Transmission | 1 | 2020 | 1178 | 0.120 |
Why?
|
| Brachial Artery | 2 | 2006 | 369 | 0.120 |
Why?
|
| India | 3 | 2006 | 2197 | 0.110 |
Why?
|
| Endothelins | 1 | 1993 | 138 | 0.110 |
Why?
|
| Access to Information | 1 | 2016 | 320 | 0.110 |
Why?
|
| Sulfonylurea Compounds | 3 | 2020 | 204 | 0.110 |
Why?
|
| Young Adult | 10 | 2022 | 56430 | 0.110 |
Why?
|
| Deferoxamine | 1 | 1993 | 151 | 0.110 |
Why?
|
| Aged | 27 | 2023 | 163280 | 0.110 |
Why?
|
| Pituitary Gland | 1 | 1996 | 665 | 0.110 |
Why?
|
| Body Temperature Regulation | 3 | 1990 | 252 | 0.110 |
Why?
|
| Diabetic Angiopathies | 2 | 1988 | 818 | 0.110 |
Why?
|
| Basal Ganglia | 1 | 2015 | 546 | 0.110 |
Why?
|
| Hospital Mortality | 2 | 2024 | 5317 | 0.110 |
Why?
|
| Cerebrum | 1 | 2013 | 137 | 0.110 |
Why?
|
| Nerve Net | 2 | 2015 | 2174 | 0.110 |
Why?
|
| Prefrontal Cortex | 2 | 2015 | 2147 | 0.100 |
Why?
|
| Patient Participation | 1 | 2021 | 1457 | 0.100 |
Why?
|
| Hypothalamus | 2 | 2008 | 1063 | 0.100 |
Why?
|
| Bone Remodeling | 1 | 2015 | 575 | 0.100 |
Why?
|
| Prediabetic State | 1 | 2017 | 499 | 0.100 |
Why?
|
| Appetite Depressants | 1 | 2012 | 110 | 0.100 |
Why?
|
| Glutamine | 2 | 2009 | 578 | 0.100 |
Why?
|
| Proteome | 1 | 2021 | 1799 | 0.100 |
Why?
|
| Emergencies | 1 | 2018 | 1170 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 9959 | 0.100 |
Why?
|
| Counseling | 1 | 2019 | 1523 | 0.100 |
Why?
|
| Cognition Disorders | 4 | 2017 | 4043 | 0.100 |
Why?
|
| Human Growth Hormone | 4 | 2021 | 683 | 0.100 |
Why?
|
| Antiporters | 1 | 1992 | 277 | 0.100 |
Why?
|
| Menstrual Cycle | 2 | 1992 | 551 | 0.100 |
Why?
|
| Phentolamine | 3 | 1987 | 104 | 0.100 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 868 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2020 | 35421 | 0.100 |
Why?
|
| Arginine | 1 | 1994 | 944 | 0.100 |
Why?
|
| Injections, Subcutaneous | 3 | 2007 | 666 | 0.100 |
Why?
|
| Ferritins | 1 | 1993 | 590 | 0.090 |
Why?
|
| Sodium, Dietary | 2 | 1994 | 418 | 0.090 |
Why?
|
| Calorimetry | 1 | 1990 | 126 | 0.090 |
Why?
|
| Acute Disease | 2 | 2020 | 7149 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2016 | 2278 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2018 | 2708 | 0.090 |
Why?
|
| C-Peptide | 7 | 1997 | 419 | 0.090 |
Why?
|
| Emergency Service, Hospital | 3 | 2018 | 7659 | 0.090 |
Why?
|
| Benzhydryl Compounds | 2 | 2020 | 845 | 0.090 |
Why?
|
| Propranolol | 4 | 1987 | 502 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2024 | 63114 | 0.090 |
Why?
|
| Antihypertensive Agents | 3 | 1998 | 2046 | 0.080 |
Why?
|
| Cost of Illness | 1 | 1998 | 1859 | 0.080 |
Why?
|
| Fructose | 2 | 1988 | 288 | 0.080 |
Why?
|
| Lipid Metabolism | 4 | 2013 | 1889 | 0.080 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 39050 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 4933 | 0.080 |
Why?
|
| Health Services Research | 1 | 1996 | 1836 | 0.080 |
Why?
|
| Emotions | 1 | 2020 | 2661 | 0.080 |
Why?
|
| Body Weight | 3 | 2017 | 4669 | 0.080 |
Why?
|
| Affect | 2 | 1999 | 1476 | 0.080 |
Why?
|
| Cerebral Cortex | 2 | 2015 | 5708 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2017 | 21746 | 0.080 |
Why?
|
| Narcotic Antagonists | 1 | 2012 | 562 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 1439 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 2029 | 0.070 |
Why?
|
| Computers | 2 | 1990 | 612 | 0.070 |
Why?
|
| Administration, Sublingual | 1 | 2006 | 56 | 0.070 |
Why?
|
| Executive Function | 1 | 2015 | 1364 | 0.070 |
Why?
|
| Cognition | 4 | 2017 | 6770 | 0.070 |
Why?
|
| Vanadates | 2 | 1995 | 82 | 0.070 |
Why?
|
| Primary Health Care | 2 | 2019 | 4558 | 0.070 |
Why?
|
| Carbohydrates | 1 | 1988 | 394 | 0.070 |
Why?
|
| Cardiovascular Diseases | 4 | 2019 | 15165 | 0.070 |
Why?
|
| Nitroglycerin | 1 | 2006 | 325 | 0.060 |
Why?
|
| Physical Exertion | 2 | 1987 | 695 | 0.060 |
Why?
|
| Double-Blind Method | 7 | 2020 | 12026 | 0.060 |
Why?
|
| Hyperemia | 1 | 2006 | 225 | 0.060 |
Why?
|
| Dexamethasone | 1 | 1992 | 1951 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2021 | 5021 | 0.060 |
Why?
|
| Occupations | 1 | 2007 | 517 | 0.060 |
Why?
|
| Energy Intake | 1 | 2012 | 2148 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2023 | 77449 | 0.060 |
Why?
|
| Energy Metabolism | 4 | 1990 | 2899 | 0.060 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 1105 | 0.060 |
Why?
|
| Subcutaneous Tissue | 1 | 2004 | 135 | 0.060 |
Why?
|
| Radioimmunoassay | 2 | 1995 | 919 | 0.060 |
Why?
|
| Sleep Deprivation | 1 | 2010 | 832 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2009 | 1121 | 0.060 |
Why?
|
| Analysis of Variance | 6 | 1997 | 6365 | 0.060 |
Why?
|
| Erythrocytes | 1 | 1992 | 2455 | 0.060 |
Why?
|
| Information Systems | 1 | 1985 | 410 | 0.050 |
Why?
|
| Kinetics | 11 | 1998 | 6473 | 0.050 |
Why?
|
| Antipsychotic Agents | 2 | 2013 | 3057 | 0.050 |
Why?
|
| Dipeptidases | 1 | 2021 | 38 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2023 | 57776 | 0.050 |
Why?
|
| Weight Gain | 1 | 2012 | 2292 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2021 | 76 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2006 | 977 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2021 | 123 | 0.050 |
Why?
|
| Delayed-Action Preparations | 2 | 2012 | 968 | 0.050 |
Why?
|
| Neuropsychological Tests | 5 | 2014 | 6993 | 0.050 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2001 | 281 | 0.050 |
Why?
|
| Leucine | 3 | 1998 | 561 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2006 | 4456 | 0.050 |
Why?
|
| Diet, Reducing | 2 | 2014 | 462 | 0.050 |
Why?
|
| Blood Pressure | 5 | 2003 | 8554 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2023 | 434 | 0.050 |
Why?
|
| Eating | 1 | 2007 | 1536 | 0.040 |
Why?
|
| Exercise | 1 | 2016 | 5615 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 11124 | 0.040 |
Why?
|
| Self-Assessment | 2 | 1998 | 390 | 0.040 |
Why?
|
| Time Factors | 8 | 2019 | 40075 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 5137 | 0.040 |
Why?
|
| Adamantane | 1 | 2020 | 173 | 0.040 |
Why?
|
| Amlodipine | 1 | 1998 | 83 | 0.040 |
Why?
|
| Risk Factors | 7 | 2014 | 72290 | 0.040 |
Why?
|
| Sex Factors | 4 | 1999 | 10397 | 0.040 |
Why?
|
| Nifedipine | 1 | 1998 | 226 | 0.040 |
Why?
|
| Adiponectin | 1 | 2004 | 1100 | 0.040 |
Why?
|
| Phosphates | 1 | 1982 | 786 | 0.040 |
Why?
|
| Abdomen | 1 | 2004 | 1118 | 0.040 |
Why?
|
| Diabetic Retinopathy | 2 | 1996 | 1210 | 0.040 |
Why?
|
| Glucosamine | 1 | 1998 | 132 | 0.040 |
Why?
|
| Aging | 3 | 1994 | 8664 | 0.040 |
Why?
|
| Dipeptides | 1 | 2020 | 409 | 0.040 |
Why?
|
| Infusions, Intravenous | 3 | 1993 | 2274 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 4931 | 0.040 |
Why?
|
| Sodium | 3 | 1993 | 1623 | 0.040 |
Why?
|
| Absenteeism | 1 | 1998 | 250 | 0.040 |
Why?
|
| Remission Induction | 1 | 2022 | 2386 | 0.040 |
Why?
|
| Calorimetry, Indirect | 3 | 2010 | 183 | 0.030 |
Why?
|
| Digestive System | 1 | 1997 | 253 | 0.030 |
Why?
|
| Pilot Projects | 3 | 2017 | 8324 | 0.030 |
Why?
|
| Hydroxycholecalciferols | 1 | 2015 | 44 | 0.030 |
Why?
|
| Glucosides | 1 | 2020 | 451 | 0.030 |
Why?
|
| Potassium | 2 | 1993 | 1336 | 0.030 |
Why?
|
| Pancreatic Hormones | 1 | 1995 | 13 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 1998 | 690 | 0.030 |
Why?
|
| Androgens | 1 | 2023 | 1281 | 0.030 |
Why?
|
| Awareness | 1 | 1999 | 640 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2021 | 1211 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2013 | 6882 | 0.030 |
Why?
|
| Pressoreceptors | 1 | 1994 | 100 | 0.030 |
Why?
|
| Recurrence | 2 | 2014 | 8340 | 0.030 |
Why?
|
| Puberty | 2 | 1989 | 490 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2023 | 1524 | 0.030 |
Why?
|
| Sympathetic Nervous System | 2 | 1990 | 514 | 0.030 |
Why?
|
| Psychomotor Performance | 2 | 1995 | 1901 | 0.030 |
Why?
|
| Luteal Phase | 2 | 1992 | 147 | 0.030 |
Why?
|
| Automobile Driving | 1 | 1999 | 431 | 0.030 |
Why?
|
| Follicular Phase | 2 | 1992 | 153 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2015 | 292 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 1377 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2014 | 105 | 0.030 |
Why?
|
| Anisotropy | 1 | 2017 | 1265 | 0.030 |
Why?
|
| United States | 4 | 2014 | 69872 | 0.030 |
Why?
|
| Oxidation-Reduction | 5 | 1994 | 2187 | 0.030 |
Why?
|
| Age Factors | 4 | 2014 | 18370 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1997 | 1590 | 0.030 |
Why?
|
| Radiography | 1 | 2004 | 7023 | 0.030 |
Why?
|
| Osmolar Concentration | 4 | 1998 | 683 | 0.030 |
Why?
|
| Neural Pathways | 2 | 2013 | 2972 | 0.030 |
Why?
|
| Placebos | 1 | 1997 | 1676 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2013 | 528 | 0.030 |
Why?
|
| Data Collection | 2 | 1996 | 3341 | 0.030 |
Why?
|
| Appetite Regulation | 1 | 2012 | 88 | 0.030 |
Why?
|
| Body Temperature | 2 | 1986 | 777 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2012 | 425 | 0.030 |
Why?
|
| Physical Fitness | 1 | 2016 | 733 | 0.030 |
Why?
|
| Angiotensin II | 1 | 1994 | 881 | 0.020 |
Why?
|
| Regression Analysis | 2 | 1998 | 6459 | 0.020 |
Why?
|
| Rats | 2 | 2021 | 24260 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2004 | 5985 | 0.020 |
Why?
|
| Renin | 1 | 1993 | 642 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2012 | 552 | 0.020 |
Why?
|
| Health Status | 2 | 1998 | 4034 | 0.020 |
Why?
|
| Lactates | 1 | 1991 | 432 | 0.020 |
Why?
|
| Software | 1 | 1985 | 4443 | 0.020 |
Why?
|
| Disease Management | 1 | 2021 | 2459 | 0.020 |
Why?
|
| Retinal Vessels | 1 | 1996 | 772 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 1996 | 969 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2023 | 40561 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2023 | 53288 | 0.020 |
Why?
|
| Proteins | 2 | 2004 | 6103 | 0.020 |
Why?
|
| Adolescent | 10 | 2007 | 85781 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2008 | 25043 | 0.020 |
Why?
|
| Intelligence | 1 | 1995 | 920 | 0.020 |
Why?
|
| Depression | 1 | 2009 | 7766 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 6489 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2010 | 168 | 0.020 |
Why?
|
| Brain Mapping | 2 | 2015 | 6669 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2015 | 1801 | 0.020 |
Why?
|
| Carbohydrate Metabolism | 1 | 1990 | 264 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1989 | 380 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2012 | 1901 | 0.020 |
Why?
|
| Stimulation, Chemical | 2 | 1989 | 326 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1994 | 1504 | 0.020 |
Why?
|
| Aldosterone | 1 | 1993 | 877 | 0.020 |
Why?
|
| Insulin-Secreting Cells | 1 | 2015 | 891 | 0.020 |
Why?
|
| Autonomic Nervous System | 1 | 1992 | 671 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 1995 | 2715 | 0.020 |
Why?
|
| Memory | 1 | 2017 | 2174 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 2429 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2012 | 1460 | 0.020 |
Why?
|
| Leg | 1 | 2012 | 1116 | 0.020 |
Why?
|
| Insulin Antibodies | 2 | 1987 | 31 | 0.020 |
Why?
|
| Communication | 1 | 2021 | 3749 | 0.020 |
Why?
|
| Thalassemia | 1 | 1988 | 273 | 0.020 |
Why?
|
| Cholesterol | 3 | 1999 | 2917 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 3798 | 0.020 |
Why?
|
| Monocytes | 3 | 1985 | 2596 | 0.020 |
Why?
|
| Equipment Design | 1 | 2015 | 3582 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1997 | 10943 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2018 | 1917 | 0.020 |
Why?
|
| Lactic Acid | 1 | 1991 | 1133 | 0.020 |
Why?
|
| Thalamus | 1 | 2012 | 1023 | 0.020 |
Why?
|
| Metoprolol | 1 | 1986 | 93 | 0.020 |
Why?
|
| Dopamine | 1 | 1993 | 1591 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2018 | 3313 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2012 | 1406 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2018 | 3528 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1990 | 1092 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 17446 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2015 | 2575 | 0.020 |
Why?
|
| Reoperation | 1 | 2014 | 4201 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 1984 | 191 | 0.020 |
Why?
|
| Health Behavior | 1 | 2016 | 2636 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 3022 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2012 | 1670 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1984 | 149 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5078 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2012 | 1881 | 0.010 |
Why?
|
| Leptin | 1 | 2012 | 1599 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2014 | 2585 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 1996 | 14722 | 0.010 |
Why?
|
| Tritium | 1 | 1984 | 745 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1996 | 3589 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1984 | 246 | 0.010 |
Why?
|
| Wakefulness | 1 | 2010 | 1245 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 12072 | 0.010 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2013 | 2305 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2016 | 3209 | 0.010 |
Why?
|
| Perception | 2 | 1999 | 1198 | 0.010 |
Why?
|
| Child | 5 | 2007 | 77709 | 0.010 |
Why?
|
| Central Nervous System Stimulants | 1 | 2010 | 1148 | 0.010 |
Why?
|
| Amino Acids | 1 | 1987 | 1736 | 0.010 |
Why?
|
| Pandemics | 1 | 2021 | 8388 | 0.010 |
Why?
|
| Incidence | 1 | 2019 | 20947 | 0.010 |
Why?
|
| Alanine | 1 | 1983 | 572 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 1996 | 19905 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2006 | 2971 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1987 | 2126 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 1814 | 0.010 |
Why?
|
| Creatinine | 1 | 1985 | 1919 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2012 | 3188 | 0.010 |
Why?
|
| Attention | 1 | 2010 | 2400 | 0.010 |
Why?
|
| Hippocampus | 1 | 2012 | 3675 | 0.010 |
Why?
|
| Keto Acids | 2 | 1990 | 34 | 0.010 |
Why?
|
| Rheumatology | 1 | 1985 | 576 | 0.010 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1985 | 1116 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2009 | 3760 | 0.010 |
Why?
|
| Imino Pyranoses | 1 | 1998 | 4 | 0.010 |
Why?
|
| 1-Deoxynojirimycin | 1 | 1998 | 18 | 0.010 |
Why?
|
| Psychotic Disorders | 1 | 2013 | 3046 | 0.010 |
Why?
|
| Attitude to Health | 1 | 1988 | 2052 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2001 | 20129 | 0.010 |
Why?
|
| Methacholine Chloride | 1 | 1998 | 233 | 0.010 |
Why?
|
| Patient Selection | 1 | 2010 | 4215 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2014 | 4468 | 0.010 |
Why?
|
| Animals | 4 | 2021 | 168757 | 0.010 |
Why?
|
| Verapamil | 1 | 1998 | 244 | 0.010 |
Why?
|
| Octreotide | 1 | 1998 | 145 | 0.010 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1981 | 245 | 0.010 |
Why?
|
| Spain | 1 | 1998 | 465 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 2356 | 0.010 |
Why?
|
| Phenylalanine | 1 | 1998 | 365 | 0.010 |
Why?
|
| Calibration | 1 | 1998 | 816 | 0.010 |
Why?
|
| Models, Biological | 1 | 2012 | 9583 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 1995 | 205 | 0.010 |
Why?
|
| Somatostatin | 1 | 1997 | 459 | 0.010 |
Why?
|
| Islets of Langerhans | 2 | 1995 | 1352 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1995 | 494 | 0.010 |
Why?
|
| Glycogen | 1 | 1994 | 260 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 1995 | 489 | 0.010 |
Why?
|
| Mental Health | 1 | 1988 | 3019 | 0.010 |
Why?
|
| Food | 1 | 1998 | 771 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2014 | 23338 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1996 | 1525 | 0.010 |
Why?
|
| Diet | 1 | 1990 | 7939 | 0.010 |
Why?
|
| Fluorescein Angiography | 1 | 1996 | 940 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 1989 | 2015 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1985 | 7913 | 0.010 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 1989 | 238 | 0.010 |
Why?
|
| Dehydroepiandrosterone | 1 | 1989 | 252 | 0.000 |
Why?
|
| Quality Assurance, Health Care | 1 | 1998 | 2212 | 0.000 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 1987 | 59 | 0.000 |
Why?
|
| Drug Delivery Systems | 1 | 1998 | 2219 | 0.000 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1995 | 2455 | 0.000 |
Why?
|
| Prognosis | 1 | 2006 | 29063 | 0.000 |
Why?
|
| Bicarbonates | 1 | 1987 | 313 | 0.000 |
Why?
|
| Retina | 1 | 1996 | 2616 | 0.000 |
Why?
|
| Body Composition | 1 | 1994 | 2401 | 0.000 |
Why?
|
| Glycolysis | 1 | 1988 | 827 | 0.000 |
Why?
|
| Catecholamines | 1 | 1984 | 387 | 0.000 |
Why?
|
| Receptor, Insulin | 1 | 1985 | 846 | 0.000 |
Why?
|
| Blood Transfusion | 1 | 1988 | 1301 | 0.000 |
Why?
|
| Perfusion | 1 | 1985 | 1360 | 0.000 |
Why?
|
| Dogs | 1 | 1985 | 3912 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1988 | 3913 | 0.000 |
Why?
|
| Pregnancy | 1 | 1989 | 29144 | 0.000 |
Why?
|